Skip to main content
. 2017 Oct 15;2017:9849823. doi: 10.1155/2017/9849823

Table 5.

RAVs to nonnucleoside NS5B inhibitors.

Resistance mutations Drugs Reference Detected resistance mutations Detected resistance mutations
Case number n = 82 N = 60
 C316Y/N/H Dasabuvir, tegobuvir, HCV796 [1316, 34] C316N 100% (60/60)
 S365T/A Tegobuvir, HCV796 [15, 16] S365F 1.2% (1/82)
S365P 1.2% (1/82)
S365A 3.33% (2/60)
 S368T Dasabuvir [14] S368A 1.2% (1/82)
S368L 1.2% (1/82)
Case number n = 4 n = 51
 M414T/I/V/L Dasabuvir, tegobuvir, HCV796 [13, 15, 16] M414Q 50% (2/4) M414L 5.88% (3/51)
 L419M/V Tegobuvir, HCV796 [15, 16] L419I 100% (4/4)
 M423T/I/V Tegobuvir, HCV796 [15, 16] M423I 1.96% (1/51)
 Y448C/H Dasabuvir, tegobuvir [1316] Y448H 1.96% (1/51)
 I482L/V/T Tegobuvir [15, 16] I482L 100% (4/4) I482T 5.88% (3/51)
I482V 1.96% (1/51)
 V494S/Q/L/A/T Tegobuvir [15, 16] V494A 50% (2/4)
V494C 25% (1/4)
V494L 3.92% (2/51)
 P495S/Q/L/A/T Tegobuvir [15, 16] P495S 5.88% (3/51)
 P496A/S Tegobuvir [15, 16] P496T 5.88% (3/51)
 V499A JTK-109, deleobuvir [15] V499A 100% (4/4) V499A 15.69% (8/51)
V499T 1.96% (1/51)
V499I 3.92% (2/51)